| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/RHEUMATOLOGY/37.8.895 |
| P698 | PubMed publication ID | 9734682 |
| P2093 | author name string | C C Mok | |
| C S Lau | |||
| R W Wong | |||
| P433 | issue | 8 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| P304 | page(s) | 895-900 | |
| P577 | publication date | 1998-08-01 | |
| P1433 | published in | British Journal of Rheumatology | Q27709787 |
| P1476 | title | Risk factors for avascular bone necrosis in systemic lupus erythematosus | |
| P478 | volume | 37 |
| Q92440239 | Avascular necrosis less frequently found in systemic lupus erythematosus patients with the use of alternate day corticosteroid |
| Q79443196 | Avascular necrosis of bilateral femoral head as a result of long-term steroid administration for radiation pneumonitis after tangential irradiation of the breast |
| Q80031892 | Avascular necrosis of the bones: an overlooked complication of pulse steroid treatment of multiple sclerosis |
| Q90185313 | Avascular necrosis of the femoral head after single steroid intra-articular injection |
| Q90602279 | Clinical characteristics of avascular necrosis in patients with Behçet disease: a case series and literature review |
| Q41867390 | Glucocorticoid-induced avascular bone necrosis: diagnosis and management |
| Q43265889 | Investigation of occurrence of osteonecrosis of the femoral head after increasing corticosteroids in patients with recurring systemic lupus erythematosus |
| Q73025113 | Kienböck's disease in systemic lupus erythematosus |
| Q89656964 | Magnesium and vitamin C supplementation attenuates steroid-associated osteonecrosis in a rat model |
| Q33893360 | Management of osteonecrosis in systemic lupus erythematosus |
| Q36960917 | Orthopedic involvement in antiphospholipid syndrome |
| Q35148600 | Osteonecrosis in patients with SLE. |
| Q36165091 | Osteonecrosis in systemic lupus erythematosus: an early, frequent, and not always symptomatic complication |
| Q42827351 | Phytomolecule icaritin incorporated PLGA/TCP scaffold for steroid-associated osteonecrosis: Proof-of-concept for prevention of hip joint collapse in bipedal emus and mechanistic study in quadrupedal rabbits. |
| Q37777642 | Prevalence and burden of pediatric-onset systemic lupus erythematosus |
| Q41919918 | Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study |
| Q84743064 | Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus |
| Q35549358 | Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? |
| Q37771692 | Steroid induced osteonecrosis: An analysis of steroid dosing risk |
| Q35671575 | Steroid-induced ischemic bone necrosis of femoral head: Treatment strategies |
| Q57603185 | Symptomatic knee osteonecrosis in patients with systemic lupus erythematosus: a case–control study |
| Q92966561 | Symptomatic multifocal avascular necrosis in an adolescent with neuropsychiatric systemic lupus erythematosus |
| Q35637240 | Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study |
| Q49835275 | Systemic lupus erythematosus patients with high disease activity are associated with accelerated incidence of osteonecrosis: a systematic review and meta-analysis |
| Q37594041 | The effects of corticosteroids on bone: osteonecrosis (avascular necrosis of the bone). |
| Q33706654 | The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK |
| Q38608906 | The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years? |
| Q53145049 | The risk factors of avascular necrosis in patients with systemic lupus erythematosus: a meta-analysis. |
| Q36324102 | The use of joint-specific and whole-body MRI in osteonecrosis: a study in patients with juvenile systemic lupus erythematosus |
| Q38920435 | Why targeted therapies are necessary for systemic lupus erythematosus |
| Q84600252 | [Osteonecrosis. What is new?] |
Search more.